I think the JMP Securities conference this week may provide a little insight into the trial results. By now the data should be "locked" and turned over to MNKD in at least the Type 1 study, if not both, and management probably has a a preliminary look at the results. While I don't expect anything more than "things are on track" or "we are encouraged" the tone of Matt's (?) presentation will tell a lot IMO...and so I couldn't help but buy a few July13 $7 calls.